XML 81 R40.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Reporting - Significant Expense of the CODM Function (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Oncology clinical trial related costs [1] $ 537,674 $ 150,777 $ 59,471
Acquired in-process research and development 0 15,007 520,915
Stock-based compensation 732,420 50,981 14,108
Total operating expenses 1,094,424 225,998 609,650
Other income, net 14,838 13,369 11,183
Interest expense 0 (8,686) (16,461)
Net loss (1,079,586) (221,315) (614,928)
Reportable Segment      
Segment Reporting Information [Line Items]      
Oncology clinical trial related costs 266,439 100,937 35,224
Acquired in-process research and development 0 15,007 520,915
Compensation related costs, excluding stock-based compensation 75,575 48,295 31,371
Stock-based compensation 732,420 50,981 14,108
Other expenses 19,990 10,778 8,032
Total operating expenses 1,094,424 225,998 609,650
Other income, net 14,838 13,369 11,183
Interest expense 0 (8,686) (16,461)
Net loss $ (1,079,586) $ (221,315) $ (614,928)
[1] Refer to Note 15 – Related Party Transactions for expenses incurred.